|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Misawa A and Inoue S: Estrogen-related
receptors in breast cancer and prostate cancer. Front Endocrinol
(Lausanne). 6:832015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mao Y, Li K, Lu L, Si-Tu J, Lu M and Gao
X: Overexpression of Cdc20 in clinically localized prostate cancer:
Relation to high Gleason score and biochemical recurrence after
laparoscopic radical prostatectomy. Cancer Biomark. 16:351–358.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xiong W, Huang C, Deng H, Jian C, Zen C,
Ye K, Zhong Z, Zhao X and Zhu L: Oncogenic non-coding RNA NEAT1
promotes the prostate cancer cell growth through the SRC3/IGF1R/AKT
pathway. Int J Biochem Cell Biol. 94:125–132. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo W, Keener AL, Jing Y, Cai L, Ai J,
Zhang J, Fisher AL, Fu G and Wang Z: FOXA1 modulates EAF2
regulation of AR transcriptional activity, cell proliferation, and
migration in prostate cancer cells. Prostate. 75:976–987. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mikami T, Yasunaga D and Kitagawa H:
Contactin-1 is a functional receptor for neuroregulatory
chondroitin sulfate-E. J Biol Chem. 284:4494–4499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lamprianou S, Chatzopoulou E, Thomas JL,
Bouyain S and Harroch S: A complex between contactin-1 and the
protein tyrosine phosphatase PTPRZ controls the development of
oligodendrocyte precursor cells. Proc Natl Acad Sci USA.
108:17498–17503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Su JL, Yang CY, Shih JY, Wei LH, Hsieh CY,
Jeng YM, Wang MY, Yang PC and Kuo ML: Knockdown of contactin-1
expression suppresses invasion and metastasis of lung
adenocarcinoma. Cancer Res. 66:2553–2561. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu JW, Wu SH, Lu RQ, Wu JG, Ni XC, Zhou
GC, Jiang HG, Zheng LH, Li XQ, Du GY and Jiang BJ: Expression and
significances of contactin-1 in human gastric cancer. Gastroenterol
Res Pract. 2013:2102052013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu P, Chen S, Wu W, Liu B, Shen W, Wang
F, He X and Zhang S: Contactin-1 (CNTN-1) overexpression is
correlated with advanced clinical stage and lymph node metastasis
in oesophageal squamous cell carcinomas. Jpn J Clin Oncol.
42:612–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu HM, Cao W, Ye D, Ren GX, Wu YN and Guo
W: Contactin 1 (CNTN1) expression associates with regional lymph
node metastasis and is a novel predictor of prognosis in patients
with oral squamous cell carcinoma. Mol Med Rep. 6:265–270.
2012.PubMed/NCBI
|
|
13
|
Yan J, Ojo D, Kapoor A, Lin X, Pinthus JH,
Aziz T, Bismar TA, Wei F, Wong N, De Melo J, et al: Neural cell
adhesion protein CNTN1 promotes the metastatic progression of
prostate cancer. Cancer Res. 76:1603–1614. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh M, Yelle N, Venugopal C and Singh
SK: EMT: Mechanisms and therapeutic implications. Pharmacol Ther.
182:80–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Smith BN and Bhowmick NA: Role of EMT in
metastasis and therapy resistance. J Clin Med. 5(pii): E172016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beuran M, Negoi I, Paun S, Ion AD, Bleotu
C, Negoi RI and Hostiuc S: The epithelial to mesenchymal transition
in pancreatic cancer: A systematic review. Pancreatology.
15:217–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu Y, Sarkissyan M and Vadgama JV:
Epithelial-mesenchymal transition and breast cancer. J Clin Med.
5(pii): E132016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang Z, Song Q, Zeng R, Li J, Li J, Lin
X, Chen X, Zhang J and Zheng Y: MicroRNA-218 inhibits EMT,
migration and invasion by targeting SFMBT1 and DCUN1D1 in cervical
cancer. Oncotarget. 7:45622–45636. 2016.PubMed/NCBI
|
|
20
|
Barrette K, Van Kelst S, Wouters J,
Marasigan V, Fieuws S, Agostinis P, van den Oord J and Garmyn M:
Epithelial-mesenchymal transition during invasion of cutaneous
squamous cell carcinoma is paralleled by AKT activation. Br J
Dermatol. 171:1014–1021. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sathe A and Nawroth R: Targeting the
PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol Biol.
1655:335–350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Murthy D, Attri KS and Singh PK:
Phosphoinositide 3-kinase signaling pathway in pancreatic ductal
adenocarcinoma progression, pathogenesis, and therapeutics. Front
Physiol. 9:3352018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao HF, Wang J, Shao W, Wu CP, Chen ZP,
To ST and Li WP: Recent advances in the use of PI3K inhibitors for
glioblastoma multiforme: Current preclinical and clinical
development. Mol Cancer. 16:1002017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang R, Sun S, Ji F, Liu C, Lin H, Xie L,
Yang H, Tang W, Zhou Y, Xu J and Li P: CNTN-1 enhances
chemoresistance in human lung adenocarcinoma through induction of
epithelial-mesenchymal transition by targeting the PI3K/Akt
pathway. Cell Physiol Biochem. 43:465–480. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan J, Wong N, Hung C, Chen WX and Tang D:
Contactin-1 reduces E-cadherin expression via activating AKT in
lung cancer. PLoS One. 8:e654632013. View Article : Google Scholar : PubMed/NCBI
|
